Remarkably, combined ARL4C knockdown and oxaliplatin treatment completely suppressed tumor growth (Figure 3F-G), suggesting that targeting ARL4C could significantly enhance oxaliplatin efficacy in CRC patients. This evidence concerns the gene ARL4C and colorectal carcinoma.